Tags

Type your tag names separated by a space and hit enter

Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians.
Cancer Epidemiol Biomarkers Prev 2002; 11(12):1555-9CE

Abstract

The myeloperoxidase (MPO) G-to-A substitution polymorphism in the promoter region of the MPO gene has been associated with a 40-70% reduction in lung cancer risk in several studies, although a recent nested case-control study disputes these findings. MPO is involved in the activation of a number of procarcinogens, including benzo(a)pyrene. The variant A allele has been shown to reduce MPO mRNA expression, thus potentially decreasing carcinogen activation. To confirm results from smaller studies, we evaluated this MPO polymorphism in 988 incident Caucasian lung cancer cases and 1128 controls. Logistic regression evaluated the association between MPO genotype and lung cancer risk, adjusting for age, gender, smoking status, time since quitting smoking, and pack-years of smoking. In the controls, the A allele frequency was 21%, and genotype distribution was in the Hardy-Weinberg equilibrium. Compared with the wild-type G/G genotype, the adjusted odds ratios for the A/A and A/G genotypes were 1.15 (95% confidence interval 0.7-1.9, P > 0.2) and 1.03 (95% confidence interval 0.8-1.3, P > 0.20), respectively. A similar lack of association was seen in analyses stratified by smoking status, median age, a number of smoking variables, disease stage, tumor grade, and histological subtype. These findings are in contrast with earlier studies suggesting a protective effect of carrying the variant A allele.

Authors+Show Affiliations

Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comment
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12496043

Citation

Xu, Li-Lian, et al. "Counterpoint: the Myeloperoxidase -463G-->a Polymorphism Does Not Decrease Lung Cancer Susceptibility in Caucasians." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 11, no. 12, 2002, pp. 1555-9.
Xu LL, Liu G, Miller DP, et al. Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1555-9.
Xu, L. L., Liu, G., Miller, D. P., Zhou, W., Lynch, T. J., Wain, J. C., ... Christiani, D. C. (2002). Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 11(12), pp. 1555-9.
Xu LL, et al. Counterpoint: the Myeloperoxidase -463G-->a Polymorphism Does Not Decrease Lung Cancer Susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1555-9. PubMed PMID: 12496043.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. AU - Xu,Li-Lian, AU - Liu,Geoffrey, AU - Miller,David P, AU - Zhou,Wei, AU - Lynch,Thomas J, AU - Wain,John C, AU - Su,Li, AU - Christiani,David C, PY - 2002/12/24/pubmed PY - 2003/4/5/medline PY - 2002/12/24/entrez SP - 1555 EP - 9 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 11 IS - 12 N2 - The myeloperoxidase (MPO) G-to-A substitution polymorphism in the promoter region of the MPO gene has been associated with a 40-70% reduction in lung cancer risk in several studies, although a recent nested case-control study disputes these findings. MPO is involved in the activation of a number of procarcinogens, including benzo(a)pyrene. The variant A allele has been shown to reduce MPO mRNA expression, thus potentially decreasing carcinogen activation. To confirm results from smaller studies, we evaluated this MPO polymorphism in 988 incident Caucasian lung cancer cases and 1128 controls. Logistic regression evaluated the association between MPO genotype and lung cancer risk, adjusting for age, gender, smoking status, time since quitting smoking, and pack-years of smoking. In the controls, the A allele frequency was 21%, and genotype distribution was in the Hardy-Weinberg equilibrium. Compared with the wild-type G/G genotype, the adjusted odds ratios for the A/A and A/G genotypes were 1.15 (95% confidence interval 0.7-1.9, P > 0.2) and 1.03 (95% confidence interval 0.8-1.3, P > 0.20), respectively. A similar lack of association was seen in analyses stratified by smoking status, median age, a number of smoking variables, disease stage, tumor grade, and histological subtype. These findings are in contrast with earlier studies suggesting a protective effect of carrying the variant A allele. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/12496043/Counterpoint:_the_myeloperoxidase__463G__>a_polymorphism_does_not_decrease_lung_cancer_susceptibility_in_Caucasians_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12496043 DB - PRIME DP - Unbound Medicine ER -